References

Amyotrophic lateral sclerosis

10.1016/s0140-6736(22)01272-7 · 2022 · External reference

Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis

10.1136/bmj-2023-075037 · 2023 · External reference

New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022

10.3389/fphar.2022.1054006 · 2022 · External reference

Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: A retrospective analysis of data from a dose-ranging study

10.1016/s1474-4422(18)30054-1 · 2018 · External reference

Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis

10.1001/jamaneurol.2021.4893 · 2022 · External reference

Neuroinflammation in amyotrophic lateral sclerosis: Role of glial activation in motor neuron disease

10.1016/s1474-4422(11)70015-1 · 2011 · External reference

Immune dysregulation in amyotrophic lateral sclerosis: Mechanisms and emerging therapies

10.1016/s1474-4422(18)30394-6 · 2019 · External reference

Neuronal STING activation in amyotrophic lateral sclerosis and frontotemporal dementia

10.1007/s00401-024-02688-z · 2024 · External reference

cGAS-STING drives ageing-related inflammation and neurodegeneration

10.1038/s41586-023-06373-1 · 2023 · External reference

TDP-43 and inflammation: Implications for amyotrophic lateral sclerosis and frontotemporal dementia

10.3390/ijms22157781 · 2021 · External reference

TDP-43 triggers mitochondrial DNA release via mPTP to activate cGAS/STING in ALS

10.1016/j.cell.2020.09.020 · 2020 · External reference

cGAS and DDX41-STING mediated intrinsic immunity spreads intercellularly to promote neuroinflammation in SOD1 ALS model

10.1016/j.isci.2022.104404 · 2022 · External reference

The cGAS-STING pathway drives neuroinflammation and neurodegeneration via cellular and molecular mechanisms in neurodegenerative diseases

10.1016/j.nbd.2024.106710 · 2024 · External reference

STING signaling in the brain: Molecular threats, signaling activities, and therapeutic challenges

10.1016/j.neuron.2023.10.014 · 2024 · External reference

Bruton's tyrosine kinase and phospholipase Cγ2 mediate chemokine-controlled B cell migration and homing

10.1016/j.immuni.2006.11.012 · 2007 · External reference

Myd88 adapter-like (Mal) is phosphorylated by Bruton's tyrosine kinase during TLR2 and TLR4 signal transduction

10.1074/jbc.m508892200 · 2006 · External reference

The B cell antigen receptor controls integrin activity through Btk and PLCγ2

10.1084/jem.20011866 · 2003 · External reference

Bruton's tyrosine kinase is a toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor κB activation by toll-like receptor 4

10.1074/jbc.m301484200 · 2003 · External reference

Treatment of patients with relapsed or refractory mantle–cell lymphoma with zanubrutinib, a selective inhibitor of Bruton's tyrosine kinase

10.1158/1078-0432.ccr-19-3703 · 2020 · External reference

Bruton's tyrosine kinase inhibitors: Recent updates

10.3390/ijms25042208 · 2024 · External reference

The MAGNOLIA trial: Zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed/refractory marginal zone lymphoma

10.1158/1078-0432.ccr-21-1704 · 2021 · External reference

BTK regulates microglial function and neuroinflammation in human stem cell models and mouse models of multiple sclerosis

10.1038/s41467-024-54430-8 · 2024 · External reference

Expression of Bruton´s tyrosine kinase in different type of brain lesions of multiple sclerosis patients and during experimental demyelination

10.3389/fimmu.2023.1264128 · 2023 · External reference

Inhibition of Bruton's tyrosine kinase modulates microglial phagocytosis: Therapeutic implications for Alzheimer's disease

10.1007/s11481-019-09839-0 · 2019 · External reference

Bruton's tyrosine kinase inhibition ameliorated neuroinflammation during chronic white matter ischemia

10.1186/s12974-024-03187-4 · 2024 · External reference

BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair

10.1007/s00401-024-02730-0 · 2024 · External reference

Standardized operational protocol for the China Human Brain Bank Consortium (2nd edition)

2024 · External reference

Standardized operational protocol for human brain banking in China

10.1007/s12264-018-0306-7 · 2019 · External reference

Large-scale differentiation of iPSC-derived motor neurons from ALS and control subjects

10.1016/j.neuron.2023.01.010 · 2023 · External reference

Inhibition of Bruton's tyrosine kinase restricts neuroinflammation following intracerebral hemorrhage

10.7150/thno.101024 · 2025 · External reference

Fenebrutinib, a Bruton's tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways

10.1186/s12974-024-03267-5 · 2024 · External reference

Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS)

10.1371/journal.pone.0009872 · 2010 · External reference

Phosphatase and tensin homologue/protein kinase B pathway linked to motor neuron survival in human superoxide dismutase 1-related amyotrophic lateral sclerosis

10.1093/brain/awq345 · 2011 · External reference

Sporadic ALS has compartment-specific aberrant exon splicing and altered cell-matrix adhesion biology

10.1093/hmg/ddp498 · 2010 · External reference

Loss of nuclear TDP-43 in amyotrophic lateral sclerosis (ALS) causes altered expression of splicing machinery and widespread dysregulation of RNA splicing in motor neurones

10.1111/nan.12148 · 2014 · External reference

Bruton's tyrosine kinase phosphorylates DDX41 and activates its binding of dsDNA and STING to initiate type 1 interferon response

10.1016/j.celrep.2015.01.039 · 2015 · External reference

Human prefrontal cortex gene regulatory dynamics from gestation to adulthood at single-cell resolution

10.1016/j.cell.2022.09.039 · 2022 · External reference

Microglia in neurodegeneration

10.1038/s41593-018-0242-x · 2018 · External reference

Single-cell RNA sequencing of microglia throughout the mouse lifespan and in the injured brain reveals complex cell-state changes

10.1016/j.immuni.2018.11.004 · 2019 · External reference

A map of transcriptional heterogeneity and regulatory variation in human microglia

10.1038/s41588-021-00875-2 · 2021 · External reference

TBK1 and IKKε act redundantly to mediate STING-induced NF-κB responses in myeloid cells

10.1016/j.celrep.2020.03.056 · 2020 · External reference

Single-cell dissection of the human motor and prefrontal cortices in ALS and FTLD

10.1016/j.cell.2024.02.031 · 2024 · External reference

Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies

10.1038/s41419-019-2158-0 · 2019 · External reference

The importance of phosphoinositide 3-kinase in neuroinflammation

10.3390/ijms252111638 · 2024 · External reference

Dysregulated phosphoinositide 3-kinase signaling in microglia: Shaping chronic neuroinflammation

10.1186/s12974-021-02325-6 · 2021 · External reference

TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation

10.1016/j.molcel.2011.01.019 · 2011 · External reference

Bruton's tyrosine kinase together with PI3-kinase are part of toll-like receptor 2 multiprotein complex and mediate LTA induced toll-like receptor 2 responses in macrophages

10.1016/j.cellsig.2006.08.013 · 2007 · External reference

Cell-autonomous immune dysfunction driven by disrupted autophagy in C9orf72-ALS iPSC-derived microglia contributes to neurodegeneration

10.1126/sciadv.abq0651 · 2023 · External reference

Onset and progression in inherited ALS determined by motor neurons and microglia

10.1126/science.1123511 · 2006 · External reference

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

10.1182/blood.2019001160 · 2019 · External reference

From development to clinical success: The journey of established and next-generation BTK inhibitors

10.1007/s10637-025-01513-y · 2025 · External reference